Literature DB >> 10980864

Epicardial gene therapy and laser revascularization.

J F Symes1.   

Abstract

Despite the proven effectiveness of coronary bypass surgery and percutaneous angioplasty techniques, an increasing number of patients are presenting with severe, medically intractable angina who are not candidates for either procedure. Two alternative strategies, transmyocardial laser revascularization and exogeneous administration of angiogenic growth factors (therapeutic angiogenesis) are currently being evaluated in such patients. This review focuses on the current status of these two procedures, emphasizing their similarities and differences in order to provide insight into what role each may ultimately play in the management of patients with otherwise unrevascularizable myocardial ischemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10980864     DOI: 10.1007/s11886-999-0060-6

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  46 in total

1.  Transmyocardial laser revascularisation.

Authors:  R Moosdorf
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

2.  Angiogenesis in transmyocardial laser revascularization. A nonspecific response to injury.

Authors:  R Malekan; C Reynolds; N Narula; S T Kelley; Y Suzuki; C R Bridges
Journal:  Circulation       Date:  1998-11-10       Impact factor: 29.690

Review 3.  Gene therapy for collateral vessel development.

Authors:  G Melillo; M Scoccianti; I Kovesdi; J Safi; T Riccioni; M C Capogrossi
Journal:  Cardiovasc Res       Date:  1997-09       Impact factor: 10.787

Review 4.  Transmyocardial laser revascularization and angiogenesis: the potential for therapeutic benefit.

Authors:  L Y Lee; T K Rosengart
Journal:  Semin Thorac Cardiovasc Surg       Date:  1999-01

5.  Neovascularization after transmyocardial laser revascularization in a model of chronic ischemia.

Authors:  G C Hughes; J E Lowe; A P Kypson; J D St Louis; A M Pippen; K G Peters; R E Coleman; T R DeGrado; C L Donovan; B H Annex; K P Landolfo
Journal:  Ann Thorac Surg       Date:  1998-12       Impact factor: 4.330

6.  Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.

Authors:  T K Rosengart; L Y Lee; S R Patel; T A Sanborn; M Parikh; G W Bergman; R Hachamovitch; M Szulc; P D Kligfield; P M Okin; R T Hahn; R B Devereux; M R Post; N R Hackett; T Foster; T M Grasso; M L Lesser; O W Isom; R G Crystal
Journal:  Circulation       Date:  1999-08-03       Impact factor: 29.690

7.  Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease.

Authors:  B Schumacher; P Pecher; B U von Specht; T Stegmann
Journal:  Circulation       Date:  1998-02-24       Impact factor: 29.690

8.  VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts.

Authors:  M D Hariawala; J R Horowitz; D Esakof; D D Sheriff; D H Walter; B Keyt; J M Isner; J F Symes
Journal:  J Surg Res       Date:  1996-06       Impact factor: 2.192

Review 9.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

10.  Left ventricular functional improvement after transmyocardial laser revascularization.

Authors:  K A Horvath; R Greene; N Belkind; B Kane; D D McPherson; D A Fullerton
Journal:  Ann Thorac Surg       Date:  1998-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.